

Peter Meyer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1514277/publications.pdf>

Version: 2024-02-01

6
papers

93
citations

1937685

4
h-index

1872680

6
g-index

6
all docs

6
docs citations

6
times ranked

197
citing authors

#	ARTICLE	IF	CITATIONS
1	Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis. <i>Blood Advances</i> , 2020, 4, 1906-1915.	5.2	35
2	Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial. <i>Blood Advances</i> , 2021, 5, 1110-1121.	5.2	33
3	Platelet Microparticles Protect Acute Myelogenous Leukemia Cells against Daunorubicin-Induced Apoptosis. <i>Cancers</i> , 2021, 13, 1870.	3.7	13
4	Consolidative Radiotherapy to Residual Masses After Chemotherapy Is Associated With Improved Outcome in Diffuse Large B-Cell Lymphoma. A Retrospective, Population-Based Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 125-135.e3.	0.4	6
5	Platelet Microparticles Decrease Daunorubicin-Induced DNA Damage and Modulate Intrinsic Apoptosis in THP-1 Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7264.	4.1	4
6	Dose-Dense Chemoimmunotherapy Including Early CNS Prophylaxis for High-Risk DLBCL. -Final Analysis from a Nordic Phase II Study (the CHIC trial). <i>Blood</i> , 2016, 128, 1854-1854.	1.4	2